✦ LIBER ✦

Low level wild-type and pre-core mutant hepatitis B viruses and hbeAg negative reactivation of chronic hepatitis B

✍ Scribed by Oketani, Makoto; Oketani, Kaoru; Xiaohong, Cui; Arima, Terukatsu

Publisher: John Wiley and Sons
Year: 1999
Tongue: English
Weight: 124 KB
Volume: 58
Category: Article
ISSN: 0146-6615
DOI: 10.1002/(sici)1096-9071(199908)58:4<332::aid-jmv3>3.0.co;2-q

No coin nor oath required. For personal study only.

✦ Synopsis

HBV-DNA; anti-HBe; antiviral therapy

📜 SIMILAR VOLUMES

Quantitative DNA analysis of low-level h

Quantitative DNA analysis of low-level hepatitis B viremia in two patients with serologically negative chronic hepatitis B

✍ Saito, Takafumi; Shinzawa, Haruhide; Uchida, Toshikazu; Kawamata, Osamu; Honma, 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 329 KB 👁 1 views

Low-level viremia due to hepatitis B virus (HBV) was demonstrated in the sera of two patients diagnosed previously as having non-B, non-C chronic hepatitis. Both patients had a "silent" HBV infection, because they were negative for both hepatitis B surface antigen (HBsAg) and anti-hepatitis B core a

Reactivation of chronic type B hepatitis

Reactivation of chronic type B hepatitis: The effect on expression of serum HBV-DNA and Pre-S encoded proteins

✍ Dr. Georg Hess; Guido Gerken; Christian Weber; Michael Manns; Karl-Hermann Meyer 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 385 KB

Hepatitis B markers were studied in seven patients with reactivated liver disease. Reactivation of chronic type B hepatitis, as indicated by the reappearance of hepatitis B e antigen (HBeAg) in the serum, was characterised by the appearance of hepatitis B virus-DNA (HBV-DNA) in the serum. The expres

Early on-treatment prediction of respons

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.